Robert S. Mannel
About
Robert S. Mannel is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Surgery.
According to data from OpenAlex, Robert S. Mannel has authored 210 papers receiving a total of 13.6k indexed citations (citations by other indexed papers that have themselves been cited), including 129 papers in Reproductive Medicine, 88 papers in Obstetrics and Gynecology and 72 papers in Surgery. Recurrent topics in Robert S. Mannel's work include Ovarian cancer diagnosis and treatment (122 papers), Endometrial and Cervical Cancer Treatments (76 papers) and Intraperitoneal and Appendiceal Malignancies (35 papers). Robert S. Mannel is often cited by papers focused on Ovarian cancer diagnosis and treatment (122 papers), Endometrial and Cervical Cancer Treatments (76 papers) and Intraperitoneal and Appendiceal Malignancies (35 papers). Robert S. Mannel collaborates with scholars based in United States, Canada and Japan. Robert S. Mannel's co-authors include Robert A. Burger, Joan L. Walker, Nick M. Spirtos, Jeffrey M. Fowler, Benjamin E. Greer, Brian N. Bundy, Mark F. Brady, Helen Huang, Michael L. Pearl and Koen DeGeest and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.
In The Last Decade
Robert S. Mannel
204 papers receiving 13.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Robert S. Mannel United States | 50 | 7.8k | 6.1k | 3.5k | 3.1k | 2.2k | 210 | 13.6k | ||
| John K. Chan United States | 60 | 5.1k 0.7× | 3.7k 0.6× | 4.1k 1.2× | 2.9k 0.9× | 1.9k 0.9× | 277 | 11.9k | ||
| Mark F. Brady United States | 42 | 8.4k 1.1× | 3.9k 0.6× | 3.7k 1.0× | 3.7k 1.2× | 2.0k 0.9× | 111 | 12.0k | ||
| C. Blake Gilks Canada | 75 | 7.2k 0.9× | 6.3k 1.0× | 4.6k 1.3× | 1.9k 0.6× | 4.6k 2.2× | 291 | 16.7k | ||
| Sandro Pignata Italy | 51 | 4.2k 0.5× | 2.0k 0.3× | 4.4k 1.2× | 2.4k 0.8× | 2.4k 1.1× | 434 | 10.6k | ||
| Ana Oaknin Spain | 39 | 4.4k 0.6× | 3.2k 0.5× | 6.8k 1.9× | 1.8k 0.6× | 3.8k 1.7× | 320 | 12.7k | ||
| Isabelle Ray‐Coquard France | 64 | 5.1k 0.7× | 2.1k 0.3× | 7.0k 2.0× | 3.6k 1.2× | 2.8k 1.3× | 418 | 16.7k | ||
| David K. Gaffney United States | 46 | 2.2k 0.3× | 4.4k 0.7× | 1.8k 0.5× | 2.0k 0.7× | 1.3k 0.6× | 318 | 9.0k | ||
| Brian N. Bundy United States | 50 | 10.0k 1.3× | 13.0k 2.1× | 4.4k 1.2× | 9.2k 3.0× | 1.9k 0.9× | 111 | 22.3k | ||
| Robert A. Soslow United States | 85 | 10.4k 1.3× | 11.2k 1.8× | 4.3k 1.2× | 3.3k 1.1× | 4.8k 2.2× | 426 | 23.6k | ||
| Byoung‐Gie Kim South Korea | 45 | 2.6k 0.3× | 2.6k 0.4× | 1.8k 0.5× | 2.1k 0.7× | 1.8k 0.8× | 318 | 7.5k |
Countries citing papers authored by Robert S. Mannel
Since
Specialization
Citations
This map shows the geographic impact of Robert S. Mannel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert S. Mannel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert S. Mannel more than expected).
Fields of papers citing papers by Robert S. Mannel
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Robert S. Mannel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert S. Mannel. The network helps show where Robert S. Mannel may publish in the future.
Co-authorship network of co-authors of Robert S. Mannel
This figure shows the co-authorship network connecting the top 25 collaborators of Robert S. Mannel. A scholar is included among the top collaborators of Robert S. Mannel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert S. Mannel. Robert S. Mannel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Zhang, Ke, Xuxin Chen, Theresa Thai, et al.. (2024). Developing a novel image marker to predict the clinical outcome of neoadjuvant chemotherapy (NACT) for ovarian cancer patients. Computers in Biology and Medicine. 172. 108240–108240.
2.
Klopp, Ann H., Danielle Enserro, Matthew A. Powell, et al.. (2024). Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. Journal of Clinical Oncology. 42(20). 2425–2435.
3.
O’Cearbhaill, Roisin E., Michael W. Sill, Steven Waggoner, et al.. (2023). PO005LBA/#1579 A randomized, phase II/III study of pegylated-liposomal-doxorubicin and atezolizumab (IND #134427) versus pegylated-liposomal-doxorubicin, bevacizumab and atezolizumab versus pegylated-liposomal-doxorubicin and bevacizumab in platinum-resistant ovarian cancer (NRG-GY009). A4–A4.
4.
Randall, Marcus E., Virginia L. Filiaci, D. Scott McMeekin, et al.. (2019). Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early-Stage Endometrial Cancer. Journal of Clinical Oncology. 37(21). 1810–1818.
5.
Ng, Chaan S., Zheng Zhang, Susanna I. Lee, et al.. (2017). CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study. Clinical Cancer Research. 23(14). 3684–3691.
6.
Oliver, Kate, William E. Brady, Michael J. Birrer, et al.. (2017). An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience. Gynecologic Oncology. 147(2). 243–249.
7.
Chakraborty, Prabir K., Soumyajit Banerjee Mustafi, Xunhao Xiong, et al.. (2017). MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nature Communications. 8(1). 14634–14634.
8.
Osborne, Raymond, Virginia L. Filiaci, Julian C. Schink, et al.. (2016). Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia. Obstetrics and Gynecology. 128(3). 535–542.
9.
Zaino, Richard J., William E. Brady, Kimberly K. Leslie, et al.. (2014). Histologic Effects of Medroxyprogesterone Acetate on Endometrioid Endometrial Adenocarcinoma. International Journal of Gynecological Pathology. 33(6). 543–553.
10.
Dewdney, Summer, Nora T. Kizer, Abegail A. Andaya, et al.. (2012). Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies. Cancer Prevention Research. 5(3). 435–443.
11.
Walker, Joan L., Marion R. Piedmonte, Nick M. Spirtos, et al.. (2012). Recurrence and Survival After Random Assignment to Laparoscopy Versus Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group LAP2 Study. Journal of Clinical Oncology. 30(7). 695–700.
12.
Burger, Robert A., Mark F. Brady, Michael A. Bookman, et al.. (2012). Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer. Obstetrical & Gynecological Survey. 67(5). 289–290.
13.
Osborne, Raymond, Virginia L. Filiaci, Julian C. Schink, et al.. (2011). Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 29(7). 825–831.
14.
Walker, Joan L., Marion Piedmonte, Nick M. Spirtos, et al.. (2010). Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study LAP2. Obstetrical & Gynecological Survey. 65(8). 503–505.
15.
Mannel, Robert S., Mark F. Brady, Elise C. Kohn, et al.. (2010). GOG 175: A Randomized phase III trial of IV carboplatin (AUC 6) and paclitaxel 175 mg/m(2) Q 21 days x 3 courses plus low-dose paclitaxel 40 mg/m(2)/wk versus IV carboplatin (AUC 6) and paclitaxel 175 mg/m(2) Q 21 days x 3 courses plus observation in patients with early-stage ovarian carcinoma. Gynecologic Oncology. 116(3).
16.
Walker, Joan L., Marion Piedmonte, Nick M. Spirtos, et al.. (2009). Laparoscopy Compared With Laparotomy for Comprehensive Surgical Staging of Uterine Cancer: Gynecologic Oncology Group Study LAP2. Journal of Clinical Oncology. 27(32). 5331–5336.
17.
Randall, Marcus E., Virginia L. Filiaci, Hyman B. Muss, et al.. (2005). Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 24(1). 36–44.
18.
Ozols, Robert F., Brian N. Bundy, Benjamin E. Greer, et al.. (2003). Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study. Journal of Clinical Oncology. 21(17). 3194–3200.
19.
Shen-Gunther, Jane, Robert S. Mannel, Joan L. Walker, Michael A. Gold, & Gary A. Johnson. (2003). Outpatient implantation of a central venous access system in gynecologic oncology patients.. PubMed. 48(11). 875–81.
20.
Broun, E. Randolph, et al.. (1997). A Phase II Trial of Edatrexate in Previously Treated Squamous Cell Cervical Cancer. American Journal of Clinical Oncology. 20(1). 78–80.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by John K. Chan Breakdown of academic impact, for papers by Mark F. Brady Breakdown of academic impact, for papers by C. Blake Gilks Breakdown of academic impact, for papers by Sandro Pignata Breakdown of academic impact, for papers by Ana Oaknin Breakdown of academic impact, for papers by Isabelle Ray‐Coquard Breakdown of academic impact, for papers by David K. Gaffney Breakdown of academic impact, for papers by Brian N. Bundy Breakdown of academic impact, for papers by Robert A. Soslow Breakdown of academic impact, for papers by Byoung‐Gie Kim